Your browser doesn't support javascript.
loading
The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
Zhou, Zhaokai; Zhang, Ge; Xu, Yudi; Yang, Shuai; Wang, Jiaojiao; Li, Zhengrui; Peng, Fu; Lu, Qiong.
Affiliation
  • Zhou Z; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
  • Zhang G; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Henan Province Key Laboratory of Cardiac Injury and Repair, Henan Province Clinical Research Center for Cardiovascular Diseases, Zhengzhou, China.
  • Xu Y; Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
  • Yang S; Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
  • Wang J; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
  • Li Z; Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Peng F; Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610
  • Lu Q; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. Electronic address: christy_luq@csu.edu.cn.
Cancer Lett ; 597: 217083, 2024 Aug 10.
Article in En | MEDLINE | ID: mdl-38925363
ABSTRACT
The U.S. Food and Drug Administration (FDA) has reported cases of T-cell malignancies, including CAR-positive lymphomas, in patients receiving B cell maturation antigen (BCMA)- or CD19-targeted autologous CAR-T cell immunotherapy. These reports were derived from clinical trials and/or post-marketing adverse event data. This finding has attracted widespread attention. Therefore, it is essential to explore the potential mechanisms by which chimeric antigen receptor (CAR)-T cell therapy triggers secondary T-cell cancers to further guarantee the safety of CAR-T cell therapy.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Immunotherapy, Adoptive / Antigens, CD19 / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Cancer Lett Year: 2024 Document type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: T-Lymphocytes / Immunotherapy, Adoptive / Antigens, CD19 / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Cancer Lett Year: 2024 Document type: Article Affiliation country: China